Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 1.00 |
| ▸ | HNF4A | P41235 | 2/20 | 1.00 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.89 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.89 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | APP | P05067 | 5/20 | 0.64 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.55 |
| ▸ | GUSB | P08236 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL673426 | 1.00 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL30075246 | 1.00 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL6266629 | 0.94 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL1048686 | 0.94 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL6266631 | 0.94 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL29938670 | 0.94 | PTPN1 (1.00) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL23143202 | 0.91 | PTPN1 (0.84) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL30075263 | 0.91 | PTPN1 (0.84) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL29759537 | 0.91 | PTPN1 (0.84) | PTPN1HNF4APTPN6PTPN2PTGS2 | |
| SCHEMBL8229587 | 0.89 | PTPN1 (0.81) | PTPN1HNF4APTPN6PTPN2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4021504-A1 | THERAPY | Vestlandets Innovasjonsselskap AS (NO) | 2022-07-06 | — | — | EP | disclosed |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | UNIV INDIANA TRUSTEES (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2021058979-A1 | THERAPY | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2021-04-01 | — | — | WO | disclosed |
| EP-3768836-A1 | ALZHEIMER'S DISEASE ANIMAL MODEL AND USE THEREOF | Tsinghua University (CN) | 2021-01-27 | — | — | EP | disclosed |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | THE TRUSTEES OF INDIANA UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| WO-2019179445-A1 | ALZHEIMER'S DISEASE ANIMAL MODEL AND USE THEREOF | TSINGHUA UNIVERSITY (CN) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | PTPN1 4322/4885HNF4A 1489/4885PTPN6 4240/4885 |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | PTPN1 4322/4885HNF4A 1489/4885PTPN6 4240/4885 |
| US-20210009498-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | PTPN1 4322/4885HNF4A 1489/4885PTPN6 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.